vs
Prestige Consumer Healthcare Inc.（PBH）与SSR MINING INC.（SSRM）财务数据对比。点击上方公司名可切换其他公司
SSR MINING INC.的季度营收约是Prestige Consumer Healthcare Inc.的1.8倍（$521.7M vs $283.4M），SSR MINING INC.净利率更高（34.8% vs 16.5%，领先18.3%），SSR MINING INC.同比增速更快（61.4% vs -2.4%），SSR MINING INC.自由现金流更多（$106.4M vs $75.3M），过去两年SSR MINING INC.的营收复合增速更高（50.5% vs 1.2%）
Prestige Consumer Healthcare Inc.是一家美国企业，主营非处方健康护理产品及家用清洁产品的营销与分销业务。该公司于1996年由Medtech Products、Prestige Brands International及Spic and Span三家公司合并成立，总部位于纽约州塔里敦，在弗吉尼亚州林奇堡设有生产工厂。
SSR Mining Inc.（前身为白银标准资源公司）总部位于美国科罗拉多州丹佛，主营金、银、铜、铅、锌矿产开采，拥有阿根廷最大的银矿，同时在美洲全境及土耳其开展矿产勘探业务。2020年与阿拉瑟黄金合并后迁至丹佛，现任总裁兼首席执行官为罗德尼·P·安塔尔。
PBH vs SSRM — 直观对比
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $283.4M | $521.7M |
| 净利润 | $46.7M | $181.5M |
| 毛利率 | 55.5% | — |
| 营业利润率 | 29.1% | 38.8% |
| 净利率 | 16.5% | 34.8% |
| 营收同比 | -2.4% | 61.4% |
| 净利润同比 | -23.5% | 3166.6% |
| 每股收益（稀释后） | $0.97 | $0.84 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $283.4M | $521.7M | ||
| Q3 25 | $274.1M | $385.8M | ||
| Q2 25 | $249.5M | $405.5M | ||
| Q1 25 | $296.5M | $316.6M | ||
| Q4 24 | $290.3M | $323.2M | ||
| Q3 24 | $283.8M | $257.4M | ||
| Q2 24 | $267.1M | $184.8M | ||
| Q1 24 | $277.0M | $230.2M |
| Q4 25 | $46.7M | $181.5M | ||
| Q3 25 | $42.2M | $65.4M | ||
| Q2 25 | $47.5M | $90.1M | ||
| Q1 25 | $50.1M | $58.8M | ||
| Q4 24 | $61.0M | $5.6M | ||
| Q3 24 | $54.4M | $10.6M | ||
| Q2 24 | $49.1M | $9.7M | ||
| Q1 24 | $49.5M | $-287.1M |
| Q4 25 | 55.5% | — | ||
| Q3 25 | 55.3% | — | ||
| Q2 25 | 56.2% | — | ||
| Q1 25 | 57.3% | — | ||
| Q4 24 | 55.5% | — | ||
| Q3 24 | 55.5% | — | ||
| Q2 24 | 54.7% | — | ||
| Q1 24 | 54.8% | — |
| Q4 25 | 29.1% | 38.8% | ||
| Q3 25 | 29.1% | 21.6% | ||
| Q2 25 | 28.8% | 26.9% | ||
| Q1 25 | 29.8% | 21.1% | ||
| Q4 24 | 31.7% | 10.6% | ||
| Q3 24 | 29.7% | 3.5% | ||
| Q2 24 | 27.0% | 5.8% | ||
| Q1 24 | 29.7% | -163.5% |
| Q4 25 | 16.5% | 34.8% | ||
| Q3 25 | 15.4% | 17.0% | ||
| Q2 25 | 19.0% | 22.2% | ||
| Q1 25 | 16.9% | 18.6% | ||
| Q4 24 | 21.0% | 1.7% | ||
| Q3 24 | 19.2% | 4.1% | ||
| Q2 24 | 18.4% | 5.2% | ||
| Q1 24 | 17.9% | -124.7% |
| Q4 25 | $0.97 | $0.84 | ||
| Q3 25 | $0.86 | $0.31 | ||
| Q2 25 | $0.95 | $0.42 | ||
| Q1 25 | $1.00 | $0.28 | ||
| Q4 24 | $1.22 | $0.03 | ||
| Q3 24 | $1.09 | $0.05 | ||
| Q2 24 | $0.98 | $0.05 | ||
| Q1 24 | $0.98 | $-1.42 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $62.4M | $575.6M |
| 总债务越低越好 | $1.0B | — |
| 股东权益账面价值 | $1.8B | $3.5B |
| 总资产 | $3.5B | $6.1B |
| 负债/权益比越低杠杆越低 | 0.56× | — |
8季度趋势，按日历期对齐
| Q4 25 | $62.4M | $575.6M | ||
| Q3 25 | $119.1M | $445.4M | ||
| Q2 25 | $139.5M | $438.5M | ||
| Q1 25 | $97.9M | $341.3M | ||
| Q4 24 | $50.9M | $417.3M | ||
| Q3 24 | $51.5M | $365.8M | ||
| Q2 24 | $34.3M | $384.4M | ||
| Q1 24 | $46.5M | $492.0M |
| Q4 25 | $1.0B | — | ||
| Q3 25 | $993.1M | — | ||
| Q2 25 | $992.7M | — | ||
| Q1 25 | $992.4M | — | ||
| Q4 24 | $992.0M | $228.6M | ||
| Q3 24 | $1.1B | $228.3M | ||
| Q2 24 | $1.1B | $228.0M | ||
| Q1 24 | $1.1B | $228.7M |
| Q4 25 | $1.8B | $3.5B | ||
| Q3 25 | $1.8B | $3.3B | ||
| Q2 25 | $1.9B | $3.3B | ||
| Q1 25 | $1.8B | $3.2B | ||
| Q4 24 | $1.8B | $3.1B | ||
| Q3 24 | $1.7B | $3.1B | ||
| Q2 24 | $1.7B | $3.1B | ||
| Q1 24 | $1.7B | $3.1B |
| Q4 25 | $3.5B | $6.1B | ||
| Q3 25 | $3.4B | $5.9B | ||
| Q2 25 | $3.4B | $5.8B | ||
| Q1 25 | $3.4B | $5.6B | ||
| Q4 24 | $3.3B | $5.2B | ||
| Q3 24 | $3.3B | $5.1B | ||
| Q2 24 | $3.3B | $5.2B | ||
| Q1 24 | $3.3B | $5.3B |
| Q4 25 | 0.56× | — | ||
| Q3 25 | 0.54× | — | ||
| Q2 25 | 0.54× | — | ||
| Q1 25 | 0.54× | — | ||
| Q4 24 | 0.55× | 0.07× | ||
| Q3 24 | 0.61× | 0.07× | ||
| Q2 24 | 0.65× | 0.07× | ||
| Q1 24 | 0.68× | 0.07× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $78.3M | $172.1M |
| 自由现金流经营现金流 - 资本支出 | $75.3M | $106.4M |
| 自由现金流率自由现金流/营收 | 26.6% | 20.4% |
| 资本支出强度资本支出/营收 | 1.1% | 12.6% |
| 现金转化率经营现金流/净利润 | 1.68× | 0.95× |
| 过去12个月自由现金流最近4个季度 | $267.2M | $241.6M |
8季度趋势，按日历期对齐
| Q4 25 | $78.3M | $172.1M | ||
| Q3 25 | $57.5M | $57.2M | ||
| Q2 25 | $79.0M | $157.8M | ||
| Q1 25 | $61.8M | $84.8M | ||
| Q4 24 | $65.1M | $95.0M | ||
| Q3 24 | $69.8M | $-1.3M | ||
| Q2 24 | $54.8M | $-78.1M | ||
| Q1 24 | $66.9M | $24.6M |
| Q4 25 | $75.3M | $106.4M | ||
| Q3 25 | $55.4M | $-2.4M | ||
| Q2 25 | $78.2M | $98.4M | ||
| Q1 25 | $58.4M | $39.3M | ||
| Q4 24 | $63.5M | $56.4M | ||
| Q3 24 | $67.8M | $-34.1M | ||
| Q2 24 | $53.6M | $-116.3M | ||
| Q1 24 | $63.8M | $-9.4M |
| Q4 25 | 26.6% | 20.4% | ||
| Q3 25 | 20.2% | -0.6% | ||
| Q2 25 | 31.3% | 24.3% | ||
| Q1 25 | 19.7% | 12.4% | ||
| Q4 24 | 21.9% | 17.5% | ||
| Q3 24 | 23.9% | -13.2% | ||
| Q2 24 | 20.1% | -62.9% | ||
| Q1 24 | 23.0% | -4.1% |
| Q4 25 | 1.1% | 12.6% | ||
| Q3 25 | 0.8% | 15.4% | ||
| Q2 25 | 0.3% | 14.7% | ||
| Q1 25 | 1.2% | 14.4% | ||
| Q4 24 | 0.5% | 11.9% | ||
| Q3 24 | 0.7% | 12.7% | ||
| Q2 24 | 0.4% | 20.7% | ||
| Q1 24 | 1.1% | 14.8% |
| Q4 25 | 1.68× | 0.95× | ||
| Q3 25 | 1.36× | 0.87× | ||
| Q2 25 | 1.66× | 1.75× | ||
| Q1 25 | 1.23× | 1.44× | ||
| Q4 24 | 1.07× | 17.10× | ||
| Q3 24 | 1.28× | -0.13× | ||
| Q2 24 | 1.12× | -8.06× | ||
| Q1 24 | 1.35× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PBH
| Womens Health | $51.8M | 18% |
| International OTC Healthcare | $47.7M | 17% |
| Gastrointestinal | $44.2M | 16% |
| Eye And Ear Care | $35.2M | 12% |
| Dermatologicals | $27.6M | 10% |
| Analgesics | $26.7M | 9% |
| Oral Care | $23.5M | 8% |
| Cough And Cold | $23.0M | 8% |
| Other Otc | $3.6M | 1% |
SSRM
| Gold | $369.3M | 71% |
| Concentrate Sales | $124.4M | 24% |
| Other | $19.1M | 4% |
| Lead | $9.0M | 2% |
